222. Primary nephrotic syndrome Clinical trials / Disease details
Clinical trials : 285 / Drugs : 285 - (DrugBank : 108) / Drug target genes : 62 - Drug target pathways : 191
Showing 1 to 10 of 285 diseases
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05267262 (ClinicalTrials.gov) | March 15, 2022 | 23/2/2022 | Study to Evaluate R3R01 in Patients With Alport Syndrome and Patients With Focal Segmental Glomerulosclerosis Study to Evaluate R3R01 in Patients With Alport Syndrome and Patients With Focal Segmental Glomerulo ... | A Phase II, Multi-center, Open-Label Study to Assess Safety, Tolerability, Efficacy and Pharmacokinetics of R3R01 in AS Patients With Uncontrolled Proteinuria on ACE/ARB Inhibition and in Patients With Primary Steroid-Resistant FSGC A Phase II, Multi-center, Open-Label Study to Assess Safety, Tolerability, Efficacy and Pharmacokine ... | Alport Syndrome;Focal Segmental Glomerulosclerosis | Drug: R3R01 | River 3 Renal Corp. | IQVIA Biotech | Not yet recruiting | 12 Years | N/A | All | 50 | Phase 2 | NULL |
| 2 | NCT05213624 (ClinicalTrials.gov) | March 14, 2022 | 27/1/2022 | A Study to Test BI 764198 in People With a Type of Kidney Disease Called Primary Focal Segmental Glomerulosclerosis A Study to Test BI 764198 in People With a Type of Kidney Disease Called Primary Focal Segmental Glo ... | A Multicenter, Randomized, Double-blind, Parallel Group, Placebo Controlled Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BI 764198 Administered Orally Once Daily for 12 Weeks in Patients With Focal Segmental Glomerulosclerosis A Multicenter, Randomized, Double-blind, Parallel Group, Placebo Controlled Study to Assess Safety, ... | Kidney Disease, Chronic | Drug: BI 764198;Drug: Placebo | Boehringer Ingelheim | NULL | Not yet recruiting | 18 Years | 75 Years | All | 60 | Phase 2 | NULL |
| 3 | EUCTR2021-004174-64-DK (EUCTR) | 08/03/2022 | 16/12/2021 | Efficacy and safety of DMX-200 in patients with focal segmental glomerulosclerosis | A pivotal Phase 3, multicenter, randomized, double-blind, placebo-controlled study of the efficacy and safety of DMX-200 in patients with focal segmental glomerulosclerosis (FSGS) who are receiving an angiotensin II receptor blocker (ARB) - ACTION3 A pivotal Phase 3, multicenter, randomized, double-blind, placebo-controlled study of the efficacy a ... | Focal segmental glomerulosclerosis MedDRA version: 21.1;Level: PT;Classification code 10067757;Term: Focal segmental glomerulosclerosis;System Organ Class: 10038359 - Renal and urinary disorders MedDRA version: 21.1;Level: LLT;Classification code 10016832;Term: Focal & segmental glomerulosclerosis;System Organ Class: 10038359 - Renal and urinary disorders;Therapeutic area: Diseases [C] - Immune System Diseases [C20] Focal segmental glomerulosclerosis MedDRA version: 21.1;Level: PT;Classification code 10067757;Term: ... | Product Name: Repagermanium Product Code: DMX-200 INN or Proposed INN: Repagermanium | Dimerix Bioscience Pty Ltd | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 286 | Phase 3 | France;United States;Taiwan;Hong Kong;Argentina;Spain;Brazil;Australia;Denmark;United Kingdom;New Zealand;Korea, Republic of France;United States;Taiwan;Hong Kong;Argentina;Spain;Brazil;Australia;Denmark;United Kingdom;New Ze ... | ||
| 4 | NCT05050214 (ClinicalTrials.gov) | March 2022 | 9/9/2021 | Obinutuzumab in Primary MN | Obinutuzumab for Primary Membranous Nephropathy: a Pilot Study in Patients With Rituximab-resistant or Rituximab-dependent Nephrotic Syndrome and in Patients Intolerant to Rituximab (the ORION Study) Obinutuzumab for Primary Membranous Nephropathy: a Pilot Study in Patients With Rituximab-resistant ... | Membranous Nephropathy | Drug: Obinutuzumab | Mario Negri Institute for Pharmacological Research | Roche S.p.a | Not yet recruiting | 18 Years | N/A | All | 20 | Phase 2 | Italy |
| 5 | EUCTR2020-003767-25-ES (EUCTR) | 25/02/2022 | 25/02/2022 | A Phase 3 study to Evaluate the Efficacy and Safety of Pegcetacoplan administered subcutaneously in Patients with C3 Glomerulopathy or Immune-Complex Membranoproliferative Glomerulonephritis A Phase 3 study to Evaluate the Efficacy and Safety of Pegcetacoplan administered subcutaneously in ... | A Phase 3, Randomized, Placebo-Controlled, Double-Blinded, Multicenter Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Patients with C3 Glomerulopathy or Immune-Complex Membranoproliferative Glomerulonephritis - VALIANT A Phase 3, Randomized, Placebo-Controlled, Double-Blinded, Multicenter Study to Evaluate the Efficac ... | complement 3 glomerulopathy (C3G)/immune complex membranoproliferative glomerulonephritis (IC-MPGN) MedDRA version: 20.0;Level: SOC;Classification code 10038359;Term: Renal and urinary disorders;System Organ Class: 10038359 - Renal and urinary disorders MedDRA version: 20.0;Level: PT;Classification code 10077827;Term: C3 glomerulopathy;System Organ Class: 10038359 - Renal and urinary disorders MedDRA version: 21.1;Level: LLT;Classification code 10027168;Term: Membranoproliferative glomerulonephritis;System Organ Class: 10038359 - Renal and urinary disorders;Therapeutic area: Diseases [C] - Immune System Diseases [C20] complement 3 glomerulopathy (C3G)/immune complex membranoproliferative glomerulonephritis(IC-MPGN) M ... | Product Name: Pegcetacoplan Product Code: APL-2 INN or Proposed INN: Pegcetacoplan Product Name: Pegcetacoplan Product Code: APL-2 INN or Proposed INN: Pegcetacoplan Product Name: Pegcetacoplan Product Code: APL-2 INN or Proposed INN: Pegcetacoplan Product Name: Pegcetacoplan Product Code: APL-2 INN or Proposed INN: Pegcetacoplan Product Name: Pegcetacoplan Product Code: APL-2 INN or Proposed INN: Pegcetacoplan Product Name: Pegcet ... | Apellis Pharmaceuticals, Inc. | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 100 | Phase 3 | United States;Czechia;Finland;Spain;Ukraine;Austria;Israel;United Kingdom;Switzerland;Italy;France;Czech Republic;Canada;Argentina;Poland;Belgium;Brazil;Peru;Australia;Netherlands;Germany;Japan;Korea, Republic of United States;Czechia;Finland;Spain;Ukraine;Austria;Israel;United Kingdom;Switzerland;Italy;France;C ... | ||
| 6 | EUCTR2020-003767-25-NL (EUCTR) | 16/02/2022 | 13/10/2021 | A Phase 3 study to Evaluate the Efficacy and Safety of Pegcetacoplan administered subcutaneously in Patients with C3 Glomerulopathy or Immune-Complex Membranoproliferative Glomerulonephritis A Phase 3 study to Evaluate the Efficacy and Safety of Pegcetacoplan administered subcutaneously in ... | A Phase 3, Randomized, Placebo-Controlled, Double-Blinded, Multicenter Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Patients with C3 Glomerulopathy or Immune-Complex Membranoproliferative Glomerulonephritis - VALIANT A Phase 3, Randomized, Placebo-Controlled, Double-Blinded, Multicenter Study to Evaluate the Efficac ... | complement 3 glomerulopathy (C3G)/immune complex membranoproliferative glomerulonephritis (IC-MPGN) MedDRA version: 20.0;Level: SOC;Classification code 10038359;Term: Renal and urinary disorders;System Organ Class: 10038359 - Renal and urinary disorders MedDRA version: 20.0;Level: PT;Classification code 10077827;Term: C3 glomerulopathy;System Organ Class: 10038359 - Renal and urinary disorders MedDRA version: 21.1;Level: LLT;Classification code 10027168;Term: Membranoproliferative glomerulonephritis;System Organ Class: 10038359 - Renal and urinary disorders;Therapeutic area: Diseases [C] - Immune System Diseases [C20] complement 3 glomerulopathy (C3G)/immune complex membranoproliferative glomerulonephritis(IC-MPGN) M ... | Product Name: Pegcetacoplan Product Code: APL-2 INN or Proposed INN: Pegcetacoplan Product Name: Pegcetacoplan Product Code: APL-2 INN or Proposed INN: Pegcetacoplan Product Name: Pegcetacoplan Product Code: APL-2 INN or Proposed INN: Pegcetacoplan Product Name: Pegcetacoplan Product Code: APL-2 INN or Proposed INN: Pegcetacoplan Product Name: Pegcetacoplan Product Code: APL-2 INN or Proposed INN: Pegcetacoplan Product Name: Pegcet ... | Apellis Pharmaceuticals, Inc. | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 100 | Phase 3 | United States;Czechia;Finland;Spain;Ukraine;Austria;Israel;United Kingdom;Switzerland;Italy;France;Czech Republic;Canada;Argentina;Poland;Brazil;Belgium;Australia;Peru;Germany;Netherlands;Japan;Korea, Republic of United States;Czechia;Finland;Spain;Ukraine;Austria;Israel;United Kingdom;Switzerland;Italy;France;C ... | ||
| 7 | EUCTR2020-003767-25-PL (EUCTR) | 08/02/2022 | 09/11/2021 | A Phase 3 study to Evaluate the Efficacy and Safety of Pegcetacoplan administered subcutaneously in Patients with C3 Glomerulopathy or Immune-Complex Membranoproliferative Glomerulonephritis A Phase 3 study to Evaluate the Efficacy and Safety of Pegcetacoplan administered subcutaneously in ... | A Phase 3, Randomized, Placebo-Controlled, Double-Blinded, Multicenter Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Patients with C3 Glomerulopathy or Immune-Complex Membranoproliferative Glomerulonephritis - VALIANT A Phase 3, Randomized, Placebo-Controlled, Double-Blinded, Multicenter Study to Evaluate the Efficac ... | complement 3 glomerulopathy (C3G)/immune complex membranoproliferative glomerulonephritis (IC-MPGN) MedDRA version: 20.0;Level: SOC;Classification code 10038359;Term: Renal and urinary disorders;System Organ Class: 10038359 - Renal and urinary disorders MedDRA version: 20.0;Level: PT;Classification code 10077827;Term: C3 glomerulopathy;System Organ Class: 10038359 - Renal and urinary disorders MedDRA version: 21.1;Level: LLT;Classification code 10027168;Term: Membranoproliferative glomerulonephritis;System Organ Class: 10038359 - Renal and urinary disorders;Therapeutic area: Diseases [C] - Immune System Diseases [C20] complement 3 glomerulopathy (C3G)/immune complex membranoproliferative glomerulonephritis(IC-MPGN) M ... | Product Name: Pegcetacoplan Product Code: APL-2 INN or Proposed INN: Pegcetacoplan Product Name: Pegcetacoplan Product Code: APL-2 INN or Proposed INN: Pegcetacoplan Product Name: Pegcetacoplan Product Code: APL-2 INN or Proposed INN: Pegcetacoplan Product Name: Pegcetacoplan Product Code: APL-2 INN or Proposed INN: Pegcetacoplan Product Name: Pegcetacoplan Product Code: APL-2 INN or Proposed INN: Pegcetacoplan Product Name: Pegcet ... | Apellis Pharmaceuticals, Inc. | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 100 | Phase 3 | United States;Czechia;Finland;Spain;Ukraine;Austria;Israel;Switzerland;United Kingdom;Italy;France;Czech Republic;Canada;Argentina;Poland;Brazil;Belgium;Australia;Peru;Netherlands;Germany;Japan;Korea, Republic of United States;Czechia;Finland;Spain;Ukraine;Austria;Israel;Switzerland;United Kingdom;Italy;France;C ... | ||
| 8 | NCT05183646 (ClinicalTrials.gov) | February 2022 | 29/11/2021 | A Study of the Efficacy and Safety of DMX-200 in Patients With FSGS Who Are Receiving an ARB | A Pivotal Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study of the Efficacy and Safety of DMX-200 in Patients With Focal Segmental Glomerulosclerosis (FSGS) Who Are Receiving an Angiotensin II Receptor Blocker (ARB) A Pivotal Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study of the Efficacy a ... | FSGS | Drug: DMX-200;Drug: Placebo | Dimerix Bioscience Pty Ltd | NULL | Not yet recruiting | 18 Years | 80 Years | All | 286 | Phase 3 | Australia;New Zealand |
| 9 | EUCTR2021-000621-27-IT (EUCTR) | 11/01/2022 | 12/10/2021 | Safety, efficacy and pharmacokinetics of sparsentan in pediatric subjects with selected kidney diseases. Safety, efficacy and pharmacokinetics of sparsentan in pediatric subjects with selected kidney disea ... | A Phase 2, Open-Label, Single-Arm, Cohort Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Sparsentan Treatment in Pediatric Subjects with Selected Proteinuric Glomerular Diseases (EPPIK). - EPPIK A Phase 2, Open-Label, Single-Arm, Cohort Study to Evaluate the Safety, Efficacy, and Pharmacokineti ... | Proteinuric glomerular diseases including:•Focal segmental glomerulosclerosis (FSGS) •Minimal change disease (MCD) •Immunoglobulin A nephropathy (IgAN) •Immunoglobulin A vasculitis (IgAV) •Alport syndrome (AS) MedDRA version: 21.1;Level: PT;Classification code 10067757;Term: Focal segmental glomerulosclerosis;System Organ Class: 10038359 - Renal and urinary disorders MedDRA version: 20.0;Classification code 10021263;Term: IgA nephropathy;System Organ Class: 10038359 - Renal and urinary disorders MedDRA version: 22.1;Level: LLT;Classification code 10082959;Term: IgA vasculitis;System Organ Class: 100000004858 MedDRA version: 20.0;Classification code 10001843;Term: Alport's syndrome;System Organ Class: 10010331 - Congenital, familial and genetic disorders MedDRA version: 21.1;Classification code 10058326;Term: Minimal change disease;System Organ Class: 10038359 - Renal and urinary disorders;Therapeutic area: Diseases [C] - Symptoms and general pathology [C23] Proteinuric glomerular diseases including:•Focal segmental glomerulosclerosis(FSGS) •Minimal change ... | Product Name: Sparsentan Product Code: [RE-021] INN or Proposed INN: Sparsentan | TRAVERE THERAPEUTICS, INC | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 57 | Phase 2 | France;United States;Spain;Poland;Netherlands;Germany;United Kingdom;Italy;Sweden | ||
| 10 | EUCTR2021-004864-81-IT (EUCTR) | 17/12/2021 | 17/09/2021 | Proposta di studio per valutare l’efficacia di Obinutuzumab, un anticorpo anti-CD20, in pazienti con nefropatia membranosa intolleranti, resistenti o dipendenti alla terapia con Rituximab (studio ORION) Proposta di studio per valutare l’efficacia di Obinutuzumab, un anticorpo anti-CD20, in pazienti con ... | Proposta di studio per valutare l’efficacia di Obinutuzumab, un anticorpo anti-CD20, in pazienti con nefropatia membranosa intolleranti, resistenti o dipendenti alla terapia con Rituximab (studio ORION) - Obinutuzumab in primary MN Proposta di studio per valutare l’efficacia di Obinutuzumab, un anticorpo anti-CD20, in pazienti con ... | PRIMARY MEMBRANOUS NEPHROPATHY MedDRA version: 21.1;Level: LLT;Classification code 10027170;Term: Membranous nephropathy;System Organ Class: 100000004857;Therapeutic area: Diseases [C] - Male diseases of the urinary and reproductive systems [C12] PRIMARY MEMBRANOUS NEPHROPATHY MedDRA version: 21.1;Level: LLT;Classification code 10027170;Term: Me ... | Trade Name: GAZYVARO - 1000 MG - CONCENTRATO PER SOLUZIONE PER INFUSIONE - USO ENDOVENOSO - FLACONCINO - 1000MG/40ML - 1 FLACONCINO Product Name: GAZYVARO Product Code: [L01XC15] INN or Proposed INN: Obitunuzumab Trade Name: OMNIPAQUE - 300 MG I/ML SOLUZIONE INIETTABILE FLACONE IN POLIPROPILENE DA 50 ML Product Name: OMNIPAQUE Product Code: [Ioexolo] INN or Proposed INN: ioexolo Trade Name: GAZYVARO- 1000 MG - CONCENTRATO PER SOLUZIONE PER INFUSIONE - USO ENDOVENOSO - FLACONCIN ... | IRCCS- ISTITUTO DI RICERCHE FARMACOLOGICHE MARIO NEGRI | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 20 | Phase 2 | Italy |